New tuberculosis vaccines approaching clinical trial - An overview

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 2, 2006, Pages 113-119

  Nasser Eddine, Ali ^a   Baumann, Sven ^a   Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DNA VACCINE; GAMMA INTERFERON; LIVE VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE;

ABSENCE OF SIDE EFFECTS; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BCG VACCINATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TUBERCULOSIS; VACCINE PRODUCTION;

EID: 33746825030     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.05.006     Document Type: Review

References (70)

1. WHO (2006) WHO Report 2006: Global Tuberculosis Control; Surveillance, Planning, Financing, pp. 1-250, WHO
2. Frieden T.R., et al. Tuberculosis. Lancet 362 (2003) 887-899
3. Saunders B.M., and Cooper A.M. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol. Cell Biol. 78 (2000) 334-341
4. Kaufmann S.H. How can immunology contribute to the control of tuberculosis?. Nat. Rev. Immunol. 1 (2001) 20-30
5. Kaufmann S.H.E., and McMichael A.J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat. Med. 11 (2005) 33-44
6. Van Deun A., et al. Tuberculosis bacteriology - priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease. ITJLD 9 (2005) 355-361
7. Glynn J.R., et al. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg. Infect. Dis. 8 (2002) 843-849
8. Calmette A., et al. Sur la vaccination preventive des enfants nouveau-nés contre la tuberculose par le BCG. Ann. Inst. Pasteur. 3 (1927) 201-208
9. Bloom B.R., and Fine P.E. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom B.R. (Ed). Tuberculosis: Pathogenesis, Protection and Control (1994), ASM Press 531-557
10. Fine P.E.M. Variation in protection by BCG - implications of and for heterologous immunity. Lancet 346 (1995) 1339-1345
11. Fine P.E.M., and Vynnycky E. The effect of heterologous immunity upon the apparent efficacy of (e.g. BCG) vaccines. Vaccine 16 (1998) 1923-1928
12. Hart P.D. Efficacy and applicability of mass BCG vaccination in tuberculosis control. Br. Med. J. 1 (1967) 587-592
13. Wilson M.E., et al. Geographic latitude and the efficacy of Bacillus-Calmette-Guerin vaccine. Clin. Infect. Dis. 20 (1995) 982-991
14. Sambandamurthy V.K., and Jacobs J. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect. 7 (2005) 955-961
15. Nasser Eddine A., and Kaufmann S.H.E. Improved protection by recombinant BCG. Microbes Infect. 7 (2005) 939-946
16. Piddington D.L., et al. Cu,Zn superoxide dismutase of Mycobacterium tuberculosis contributes to survival in activated macrophages that are generating an oxidative burst. Infect. Immun. 69 (2001) 4980-4987
17. Kamath A.T., et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23 (2005) 3753-3761
18. Doherty T.M., and Andersen P. Vaccines for tuberculosis: novel concepts and recent progress. Clin. Microbiol. Rev. 18 (2005) 687-702
19. Andersen P., and Doherty T.M. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat. Rev. Micro 3 (2005) 656-662
20. Behr M.A., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 (1999) 1520-1523
21. Pym A.S., et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9 (2003) 533-539
22. Horwitz M.A., and Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71 (2003) 1672-1679
23. Horwitz M.A. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect. 7 (2005) 947-954
24. Horwitz M.A., et al. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. U S A 97 (2000) 13853-13858
25. Fruth U., and Young D. Prospects for new TB vaccines: stop TB working group on TB vaccine development. ITJLD 8 (2004) 151-155
26. von Reyn C.F., and Vuola J.M. New vaccines for the prevention of tuberculosis. Clin. Infect. Dis. 35 (2002) 465-474
27. Grode L., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 115 (2005) 2472-2479
28. D'Souza S., et al. Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect. Immun. 71 (2003) 483-493
29. Reed S.G., et al. Prospects for a better vaccine against tuberculosis. Tuberculosis 83 (2003) 213-219
30. Hess J., et al. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. U S A 95 (1998) 5299-5304
31. Glomski I.J., et al. The Listeria monocytogenes hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to infected host cells. J. Cell Biol. 156 (2002) 1029-1038
32. van der Zanden A.G.M., et al. Improvement of differentiation and interpretability of spoligotyping for Mycobacterium tuberculosis complex isolates by introduction of new spacer oligonucleotides. J. Clin. Microbiol. 40 (2002) 4628-4639
33. Kaufmann S.H.E. Immunity to intracellular bacteria. Annu. Rev. Immunol. 11 (1993) 129-163
34. Rogers H.W., et al. Listeria monocytogenes induces apoptosis of infected hepatocytes. J. Immunol. 156 (1996) 679-684
35. Winau F., et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24 (2006) 105-117
36. Schaible U.E., et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat. Med. 9 (2003) 1039-1046
37. Cole S.T., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998) 537-544
38. Huygen K., et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 2 (1996) 893-898
39. Lowrie D.B., et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 400 (1999) 269-271
40. Kamath A.T., et al. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect. Immun. 67 (1999) 1702-1707
41. Lowrie D.B., et al. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 15 (1997) 834-838
42. Zhu X., et al. Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection. Immunology 92 (1997) 6-9
43. Andersen P., and Doherty T.M. TB subunit vaccines - putting the pieces together. Microbes Infect. 7 (2005) 911-921
44. Temmerman S., et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat. Med. 10 (2004) 935-941
45. Mollenkopf H.J., et al. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect. Immun. 72 (2004) 6471-6479
46. Andersen P. TB vaccines: progress and problems. Trends Immunol. 22 (2001) 160-168
47. Pinto A.K., and Hill A.B. Viral interference with antigen presentation to CD8+ T cells: lessons from cytomegalovirus. Viral Immunol. 18 (2005) 434-444
48. McShane H., et al. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis 85 (2005) 47-52
49. McShane H. Developing an improved vaccine against tuberculosis. Expert Rev. Vaccines 3 (2004) 299-306
50. Goonetilleke N.P., et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171 (2003) 1602-1609
51. McShane H., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10 (2004) 1240-1244
52. Lang T., et al. New TB vaccine granted orphan drug status. BMJ 331 (2005) 1476
53. Vogels R., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77 (2003) 8263-8271
54. Skeiky Y.A.W., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172 (2004) 7618-7628
55. Brandt L., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M-tuberculosis-infected guinea pigs. Infect. Immun. 72 (2004) 6622-6632
56. Langermans J.A.M., et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23 (2005) 2740-2750
57. Olsen A.W., et al. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72 (2004) 6148-6150
58. Doherty T.M., et al. Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J. Infect. Dis. 190 (2004) 2146-2153
59. Lingnau K., et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 20 (2002) 3498-3508
60. Olsen A.W., et al. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect. Immun. 69 (2001) 2773-2778
61. Peppoloni S., et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2 (2003) 285-293
62. Doherty T.M., et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J. Clin. Microbiol. 40 (2002) 704-706
63. Dietrich J., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. 174 (2005) 6332-6339
64. Parra M., et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect. Immun. 72 (2004) 6799-6805
65. Pai M., et al. Interferon-[gamma] assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4 (2004) 761-776
66. Ehrt S., et al. Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J. Exp. Med. 194 (2001) 1123-1139
67. Mollenkopf H.J., et al. Transcriptional responses in mouse lungs induced by vaccination with Mycobacterium bovis BCG and infection with Mycobacterium tuberculosis. Microbes Infect. 8 (2006) 136-144
68. Jacobsen, M. et al. Deconfounding microarray analyses: a novel approach to resolve inconsistencies in heterogeneous tissues. Methods Inf. Med. (in press)
69. Jacobsen M., et al. Ras-associated small GTPase 33A, a novel T cell factor, is down-regulated in patients with tuberculosis. J. Infect. Dis. 192 (2005) 1211-1218
70. Tsenova L., et al. Evaluation of the Mtb72F Polyprotein Vaccine in a Rabbit Model of Tuberculous Meningitis. Infect. Immun. 74 (2006) 2392-2401